Revolution Medicines (RVMD) news

Revolution Medicines, Inc.: RBC raises target price to $260 from $259

Revolution Medicines, Inc. (RVMD) has seen recent analyst activity that reflects a cautiously optimistic outlook for the clinical-stage biotechnology firm. On October 23, 2023, Oppenheimer maintained its "Outperform" rating for the company and raised its price target to $260 from $230, representing…

Refile-Publicis - Q3 net revenue EUR 3.81 bln, up 7.9% y/y (removes extraneous product codes)

Publicis Group reported third-quarter net revenue of €3.81 billion, representing a 7.9% year-over-year increase, according to the company’s latest financial update. This growth reflects the firm’s ongoing performance in the advertising and marketing services sector, despite broader economic and…

LVMH CFO: Dior is positive year-to-date, Q3 is flat

LVMH CFO: Vuitton performance in Q3 was not very far from average

LVMH’s Chief Financial Officer noted in a recent update that the performance of the Vuitton brand in the third quarter was "not very far from average," according to internal assessments. This observation aligns with the company’s projected Q3 sales of 17.99 billion euros, which reflect a 1% organic…

LVMH CFO: Middle East situation still a headwind, selfhelp is a priority

LVMH CFO Jean-Jacques Guiony reiterated on October 12, 2026, that the ongoing situation in the Middle East continues to pose challenges for the luxury goods giant. Speaking during a financial update, Guiony emphasized that while the company remains optimistic about long-term growth, the…